IDH1 and acute myeloid leukemia: In the corresponding unweighted study cohort (IDH1/2wildtype versus IDH2mutated), cardiac function declined without differences between IDH1/2wildtype and IDH2mutated patients at earlier time points (t1–t2) during AML therapy, while at the latest time point t3IDH2mutated patients exhibited a significantly reduced LVEF (t3: absolute LVEF reduction −8.8%, 95%CI −18.78 to 1.18, p = 0.028) compared to IDH1/2wildtype patients (Fig. 4b and Supplementary Table S5 in the Data Supplement).